HEADER HYDROLASE/HYDROLASE INHIBITOR 18-MAY-11 3S43 TITLE HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG TITLE 2 AMPRENAVIR COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A; COMPND 4 EC: 3.4.23.16; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: PROTEASE; COMPND 9 CHAIN: B; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21 (DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET11A; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 12 ORGANISM_TAXID: 11676; SOURCE 13 GENE: POL; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 15 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 16 EXPRESSION_SYSTEM_STRAIN: BL21 (DE3); SOURCE 17 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS AMPRENAVIR, HIV/AIDS, DRUG RESISTANCE, ASPARTIC PROTEASE, MOLECULAR KEYWDS 2 RECOGNITION, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR Y.-F.WANG,Y.-F.TIE,I.T.WEBER REVDAT 2 13-SEP-23 3S43 1 REMARK SEQADV REVDAT 1 21-MAR-12 3S43 0 JRNL AUTH Y.TIE,Y.F.WANG,P.I.BOROSS,T.Y.CHIU,A.K.GHOSH,J.TOZSER, JRNL AUTH 2 J.M.LOUIS,R.W.HARRISON,I.T.WEBER JRNL TITL CRITICAL DIFFERENCES IN HIV-1 AND HIV-2 PROTEASE SPECIFICITY JRNL TITL 2 FOR CLINICAL INHIBITORS. JRNL REF PROTEIN SCI. V. 21 339 2012 JRNL REFN ISSN 0961-8368 JRNL PMID 22238126 JRNL DOI 10.1002/PRO.2019 REMARK 2 REMARK 2 RESOLUTION. 1.26 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.26 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 91.5 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.162 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.160 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.200 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 2926 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 58559 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.146 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.143 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.182 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 2331 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 46557 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1514 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 64 REMARK 3 SOLVENT ATOMS : 126 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1662.6 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1635.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 21 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 16418 REMARK 3 NUMBER OF RESTRAINTS : 21829 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.013 REMARK 3 ANGLE DISTANCES (A) : 0.031 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.028 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.063 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.064 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.028 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.004 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.058 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.078 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: CONJUGAGE GRADIENT MINIMIZATION REMARK 4 REMARK 4 3S43 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-JUN-11. REMARK 100 THE DEPOSITION ID IS D_1000065735. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-MAR-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 58771 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.260 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 91.3 REMARK 200 DATA REDUNDANCY : 3.700 REMARK 200 R MERGE (I) : 0.06300 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.26 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.31 REMARK 200 COMPLETENESS FOR SHELL (%) : 59.9 REMARK 200 DATA REDUNDANCY IN SHELL : 2.00 REMARK 200 R MERGE FOR SHELL (I) : 0.36100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 3DJK REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.77 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.72 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: FROM A 3.5MG/ML PROTEIN SOLUTION AT PH REMARK 280 5.4 WITH 0.175M KI, 0.1M CITRATE PHOSPHATE, 4% DMSO. 1.0UL WELL REMARK 280 SOLUTION WITH 1.5UL PROTEIN SOLUTION. THE INHIBITOR WAS MIXED REMARK 280 WITH PROTEASE IN A RATIO 5:1, EVAPORATION, TEMPERATURE 298K, REMARK 280 VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 29.18700 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.28250 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.18700 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.28250 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3620 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9790 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -22.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 NE - CZ - NH2 ANGL. DEV. = -4.4 DEGREES REMARK 500 ASP A 29 CB - CG - OD1 ANGL. DEV. = 6.8 DEGREES REMARK 500 ARG A 41 CD - NE - CZ ANGL. DEV. = 27.4 DEGREES REMARK 500 ARG A 57 CD - NE - CZ ANGL. DEV. = 25.0 DEGREES REMARK 500 ASP B 130 CB - CG - OD1 ANGL. DEV. = -5.8 DEGREES REMARK 500 ASP B 130 CB - CG - OD2 ANGL. DEV. = 6.6 DEGREES REMARK 500 LYS B 143 CA - CB - CG ANGL. DEV. = 15.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO B 179 99.44 -69.96 REMARK 500 PRO B 179 61.06 -69.95 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 478 A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 504 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 508 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 510 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 514 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 515 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 516 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD A 518 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 532 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 505 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 506 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 507 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 511 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 512 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 513 REMARK 800 REMARK 800 SITE_IDENTIFIER: CC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IOD B 517 REMARK 800 REMARK 800 SITE_IDENTIFIER: CC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B 531 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3NU3 RELATED DB: PDB REMARK 900 WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NU4 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE MUTANT V32I WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3S53 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH DARUNAVIR IN REMARK 900 SPACE GROUP P212121 REMARK 900 RELATED ID: 3S54 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH DARUNAVIR IN REMARK 900 SPACE GROUP P21212 REMARK 900 RELATED ID: 3S56 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH SAQUINAVIR DBREF 3S43 A 1 99 UNP Q7SSE3 Q7SSE3_9HIV1 1 99 DBREF 3S43 B 101 199 UNP Q7SSE3 Q7SSE3_9HIV1 1 99 SEQADV 3S43 LYS A 7 UNP Q7SSE3 GLN 7 ENGINEERED MUTATION SEQADV 3S43 ILE A 32 UNP Q7SSE3 VAL 32 ENGINEERED MUTATION SEQADV 3S43 ILE A 33 UNP Q7SSE3 LEU 33 ENGINEERED MUTATION SEQADV 3S43 VAL A 47 UNP Q7SSE3 ILE 47 ENGINEERED MUTATION SEQADV 3S43 ILE A 63 UNP Q7SSE3 LEU 63 ENGINEERED MUTATION SEQADV 3S43 ALA A 67 UNP Q7SSE3 CYS 67 ENGINEERED MUTATION SEQADV 3S43 HIS A 69 UNP Q7SSE3 TYR 69 ENGINEERED MUTATION SEQADV 3S43 ALA A 95 UNP Q7SSE3 SER 95 ENGINEERED MUTATION SEQADV 3S43 LYS B 107 UNP Q7SSE3 GLN 7 ENGINEERED MUTATION SEQADV 3S43 ILE B 132 UNP Q7SSE3 VAL 32 ENGINEERED MUTATION SEQADV 3S43 ILE B 133 UNP Q7SSE3 LEU 33 ENGINEERED MUTATION SEQADV 3S43 VAL B 147 UNP Q7SSE3 ILE 47 ENGINEERED MUTATION SEQADV 3S43 ILE B 163 UNP Q7SSE3 LEU 63 ENGINEERED MUTATION SEQADV 3S43 ALA B 167 UNP Q7SSE3 CYS 67 ENGINEERED MUTATION SEQADV 3S43 HIS B 169 UNP Q7SSE3 TYR 69 ENGINEERED MUTATION SEQADV 3S43 ALA B 195 UNP Q7SSE3 SER 95 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR ILE ILE GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLU ILE ILE ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO ILE ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR ILE ILE GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO ILE ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET 478 A 401 42 HET IOD A 502 1 HET IOD A 504 1 HET IOD A 508 1 HET IOD A 510 1 HET IOD A 514 1 HET IOD A 515 1 HET IOD A 516 1 HET IOD A 518 1 HET GOL A 532 8 HET IOD B 501 1 HET IOD B 503 1 HET IOD B 505 1 HET IOD B 506 1 HET IOD B 507 1 HET IOD B 511 1 HET IOD B 512 1 HET IOD B 513 1 HET IOD B 517 1 HET GOL B 531 8 HETNAM 478 {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL- HETNAM 2 478 2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL HETNAM 3 478 ESTER HETNAM IOD IODIDE ION HETNAM GOL GLYCEROL HETSYN 478 AMPRENAVIR HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 478 C25 H35 N3 O6 S FORMUL 4 IOD 17(I 1-) FORMUL 12 GOL 2(C3 H8 O3) FORMUL 23 HOH *126(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 186 THR B 191 1 6 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N ASN A 98 O THR B 196 SHEET 4 A 4 GLN B 102 ILE B 103 -1 O ILE B 103 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O GLN A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O HIS A 69 N ILE A 66 SHEET 4 B 8 THR A 31 ILE A 33 1 N ILE A 33 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 O ILE A 84 N ILE A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N ILE A 13 O LYS A 20 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 143 GLY B 149 0 SHEET 2 C 8 GLY B 152 ILE B 166 -1 O GLN B 158 N LYS B 143 SHEET 3 C 8 HIS B 169 VAL B 177 -1 O HIS B 169 N ILE B 166 SHEET 4 C 8 ILE B 132 ILE B 133 1 N ILE B 133 O LEU B 176 SHEET 5 C 8 ILE B 184 ILE B 185 -1 O ILE B 184 N ILE B 132 SHEET 6 C 8 GLN B 118 LEU B 124 1 N LEU B 123 O ILE B 185 SHEET 7 C 8 LEU B 110 ILE B 115 -1 N ILE B 113 O LYS B 120 SHEET 8 C 8 GLY B 152 ILE B 166 -1 O GLU B 165 N LYS B 114 SITE 1 AC1 20 ASP A 25 GLY A 27 ALA A 28 ASP A 30 SITE 2 AC1 20 ILE A 32 GLY A 48 GLY A 49 ILE A 50 SITE 3 AC1 20 HOH A1001 HOH A1127 HOH A1128 ASP B 125 SITE 4 AC1 20 GLY B 127 ALA B 128 ASP B 129 ASP B 130 SITE 5 AC1 20 VAL B 147 GLY B 148 GLY B 149 ILE B 150 SITE 1 AC2 1 THR A 74 SITE 1 AC3 3 THR A 12 LYS A 14 GLY A 68 SITE 1 AC4 1 THR A 12 SITE 1 AC5 1 GLU A 21 SITE 1 AC6 1 GLY A 48 SITE 1 AC7 1 IOD A 516 SITE 1 AC8 2 IOD A 515 HOH A1029 SITE 1 AC9 3 GLN A 18 SER A 37 IOD B 517 SITE 1 BC1 6 PRO A 39 GLY A 40 ARG A 41 TYR A 59 SITE 2 BC1 6 ASP A 60 GLU A 61 SITE 1 BC2 2 TRP B 106 LYS B 155 SITE 1 BC3 1 HOH B1136 SITE 1 BC4 2 ILE B 163 HOH B1111 SITE 1 BC5 1 IOD B 507 SITE 1 BC6 2 THR B 112 IOD B 506 SITE 1 BC7 1 GLY B 140 SITE 1 BC8 3 THR B 174 ASN B 188 HOH B1062 SITE 1 BC9 1 HOH B1055 SITE 1 CC1 1 IOD A 518 SITE 1 CC2 7 GLN A 2 THR A 4 TRP A 6 GLY A 51 SITE 2 CC2 7 ILE B 154 PRO B 179 HOH B1091 CRYST1 58.374 86.565 46.306 90.00 90.00 90.00 P 21 21 2 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017131 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011552 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021595 0.00000